Allogene Therapeutics (ALLO) Current Assets (2018 - 2026)

Allogene Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $273.3 million for Q1 2026.

• In Q1 2026, Current Assets fell 6.27% year-over-year to $273.3 million; the TTM figure through Mar 2026 stood at $273.3 million (down 6.27% YoY), while the FY2025 annual figure was $257.7 million, down 15.04% from the prior year.
• Current Assets came in at $273.3 million for Q1 2026 at Allogene Therapeutics, up from $257.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $569.1 million in Q3 2022 to a low of $257.7 million in Q4 2025.
• A 5-year average of $401.4 million and a median of $457.1 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets climbed 13.17% in 2022 and plunged 38.17% in 2025, its largest moves.
• Allogene Therapeutics' Current Assets stood at $528.8 million in 2022, then slipped by 13.18% to $459.1 million in 2023, then slumped by 33.92% to $303.4 million in 2024, then dropped by 15.04% to $257.7 million in 2025, then advanced by 6.03% to $273.3 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $273.3 million, $257.7 million, and $260.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison